-
Article
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Dickkopf-related protein 1 (DKK1) is a Wingless-related integrate site (Wnt) signaling modulator that is upregulated in prostate cancers (PCa) with low androgen receptor expression. DKN-01, an IgG4 that neutra...
-
Article
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
Inactivating mutations in LKB1/STK11 are present in roughly 20% of nonsmall cell lung cancers (NSCLC) and portend poor response to anti-PD-1 immunotherapy. Unexpectedly, we found that LKB1 deficiency correlated w...
-
Chapter and Conference Paper
Network Cooperation with Progressive Disambiguation for Partial Label Learning
Partial Label Learning (PLL) aims to train a classifier when each training instance is associated with a set of candidate labels, among which only one is correct but is not accessible during the training phase...
-
Article
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment
Immunotherapy has recently been shown to improve outcomes for advanced PD-L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA approval of the first immune checkpoint inhi...
-
Article
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Physiological Stat3 signaling is temporally restricted. In cancer, Stat3 activity is often persistently elevated and fosters progression through its effects on tumor cells and their microenvironment. This repo...
-
Article
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
Tumors generate microenvironments that actively suppress the body's anti-tumor immune response. Kortylewski et al. restore immunity by delivering an siRNA against Stat3, a regulator of immune suppression, to myel...
